Why Partner With PathoQuest

Why PARTNER WITH PathoQuest?

At PathoQuest, we understand the critical need to develop your innovative biologics safely and rapidly in a complex testing environment.

PathoQuest provides a validated Next Generation Sequencing (NGS) approach in biosafety testing to biologics characterization and release, for global biopharmaceutical and emerging biologics companies.

What we do

With a proven track record in biotesting, PathoQuest offers a team of NGS Quality Control (QC) testing experts based in France and the U.S. Our expert Contract Research Organization (CRO) team is readily available to support with rapid and robust QC testing at both GMP and non-GMP levels, emphasizing our commitment to biosafety service.

What we do

With a proven track record in biotesting, PathoQuest offers a team of NGS Quality Control (QC) testing experts based in France and the U.S. Our expert Contract Research Organization (CRO) team is readily available to support with rapid and robust QC testing at both GMP and non-GMP levels, emphasizing our commitment to biosafety service.

How we do it

Rapid and Safe

We understand your needs in delivering your life changing biologic to patients

Pioneering Expertise

Our leading specialists provide testing for emerging and established clients

GMP

Our services offer the highest levels of regulatory compliance

Global Reach

Sites in U.S. and France are located close to you and your leading markets

Ethical Biologic QC

We pride ourselves on leading the industry for animal free testing

How we do it

Rapid and Safe

We understand your needs in delivering your life changing biologic to patients

Pioneering Expertise

Our leading specialists provide testing for emerging and established clients

GMP

Our services offer the highest levels of regulatory compliance

Global Reach

Sites in U.S. and France are located close to you and your leading markets

Ethical Biologic QC

We pride ourselves on leading the industry for animal free testing

OUR HAPPY CUSTOMERS

“Our partnership with PathoQuest represents a significant step forward in our commitment to empower tomorrow’s therapies today. PathoQuest’s expertise in NGS technology will greatly enhance our capabilities and allow us to deliver even greater value to our clients through our comprehensive viral vector services, from process development to cGMP manufacturing for clinical and commercial supply.”

Robert Panting
General Manager
Rentschler Biopharma, ATMP

“IAVI has chosen to work with PathoQuest as the iDTECT Virome approach has permitted us to adopt next generation sequencing (NGS) for viral safety testing, replacing the traditional in vivo and in vitro testing for the release of our vaccine vectors in a safe and timely manner. We also appreciate their virology expertise in trouble-shooting and problem-solving for safety testing of our viral vectors.”

Eddy Sayeed
Executive Director, Process Development & Vaccine Manufacturing/Vaccine
IAVI

“We have been impressed by PathoQuest’s excellent service. They supported us with their NGS-based Quality Control platform, enabling us to navigate technical and regulatory hurdles to reach a key milestone. PathoQuest has been a reliable and trustworthy partner for biosafety testing.”

Jack Elands, PhD
Former Chief Executive Officer
Emergence Therapeutics AG (recently acquired by Eli Lilly)

“We chose PathoQuest NGS viral safety tests for rapid and reliable Quality Control of our therapeutic cancer vaccine in development, ensuring batch release in weeks instead of months”

Christophe Ancel, PharmD
V.P. Pharmaceutical Operations & Qualified Person
Transgene SA

“Our collaboration with PathoQuest is helping our customers overcoming the limitations of traditional QC methods. As a CDMO, using PathoQuest’s NGS assays, we can advance our customers projects safely, while ensuring timelines are met.”

Nicolas Salavin
Head of Transformation & Integration
Oxford Biomedica (CDMO)